AnaptysBio Hits New 52-Week High After Analyst Upgrade

Biotech firm's stock reaches new high following Barclays price target increase

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) reached a new 52-week high on Wednesday after Barclays raised its price target on the stock from $78.00 to $79.00 and maintained an overweight rating. The biotech company's stock traded as high as $58.50 before closing at $58.47, up 12.8% on the day.

Why it matters

The analyst upgrade and new 52-week high for AnaptysBio's stock price reflects growing investor confidence in the company's pipeline of immunology and inflammation-focused therapeutic antibodies. As a clinical-stage biotech firm, positive developments like this can significantly impact the company's valuation and access to capital.

The details

Barclays cited the company's promising drug candidates and ongoing clinical trials as reasons for the price target increase. AnaptysBio is developing several antibody therapies to treat various dermatological and inflammatory disorders. The company has multiple programs in clinical-stage development, including treatments for atopic dermatitis, eosinophilic esophagitis, and chronic obstructive pulmonary disease.

  • On Wednesday, March 4, 2026, AnaptysBio's stock reached a new 52-week high of $58.50.

The players

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation.

Barclays

A multinational investment bank and financial services company that raised its price target on AnaptysBio's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The new 52-week high for AnaptysBio's stock price underscores the market's optimism about the company's pipeline of innovative immunology and inflammation therapies. As a clinical-stage biotech firm, positive developments like this analyst upgrade can significantly impact the company's valuation and access to capital as it continues advancing its drug candidates through the clinical trial process.